Lilly secures funding for AD trials

TPG-Axon (New York, N.Y.) and Quintiles' NovaQuest unit will provide Eli Lilly (NYSE:LLY) about $300 million for Phase III trials of the gamma secretase inhibitor LY450139 and an unnamed antibody agai...